Jilin Province Xidian Pharmaceutical Sci-Tech Development Co.,Ltd (SHE:301130)
China · Delayed Price · Currency is CNY 26.52
-1.10 (-3.98%)
Sep 10, 2026, 3:04 PM CST
SHE:301130 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 207.51 | 234.4 | 255.25 | 225.14 | 255.4 | 285.14 |
Other Revenue | 0.44 | 0.44 | 1.16 | 0.35 | 0.07 | 0.51 |
| 207.96 | 234.84 | 256.41 | 225.49 | 255.47 | 285.66 | |
Revenue Growth | -18.69% | -8.41% | 13.71% | -11.73% | -10.57% | -0.23% |
Cost of Revenue | 55.22 | 57.04 | 61.16 | 45.52 | 47.42 | 46.98 |
Gross Profit | 152.74 | 177.8 | 195.24 | 179.97 | 208.05 | 238.68 |
Selling, General & Admin | 143.02 | 147.93 | 145.14 | 142.59 | 153.66 | 168.88 |
Research & Development | 10.55 | 11.25 | 10.22 | 8.7 | 11.74 | 13.31 |
Other Operating Expenses | 1.81 | 3.07 | 1.65 | 2.45 | 6.42 | 7.92 |
Operating Expenses | 155.22 | 162.1 | 157.68 | 153.2 | 171.77 | 190.43 |
Operating Income | -2.48 | 15.7 | 37.57 | 26.77 | 36.28 | 48.25 |
Interest Expense | -0.44 | -0.44 | -0.07 | -0.05 | - | - |
Interest & Investment Income | 3.09 | 3.45 | 6.82 | 13.35 | 11.36 | 3.85 |
Other Non Operating Income (Expenses) | -0.12 | -0.02 | -0.04 | -0.05 | -0.01 | -0.04 |
EBT Excluding Unusual Items | 0.03 | 18.68 | 44.28 | 40.01 | 47.63 | 52.05 |
Gain (Loss) on Sale of Investments | 0.7 | 0.94 | 0.74 | 3.15 | 1.17 | - |
Gain (Loss) on Sale of Assets | - | - | -0.5 | 1.87 | - | - |
Asset Writedown | -0.01 | -0 | -0 | -0.17 | -0 | -0.17 |
Other Unusual Items | 1.38 | 1.38 | 2 | 13.45 | 1.64 | 7.32 |
Pretax Income | 2.11 | 21 | 46.51 | 58.31 | 50.43 | 59.21 |
Income Tax Expense | -2.13 | 1.1 | 6.25 | 7.81 | 9.71 | 7.19 |
Earnings From Continuing Operations | 4.24 | 19.9 | 40.27 | 50.5 | 40.72 | 52.02 |
Minority Interest in Earnings | 1.64 | 2 | - | - | - | - |
Net Income | 5.88 | 21.9 | 40.27 | 50.5 | 40.72 | 52.02 |
Net Income to Common | 5.88 | 21.9 | 40.27 | 50.5 | 40.72 | 52.02 |
Net Income Growth | -85.57% | -45.62% | -20.26% | 24.01% | -21.71% | 4.58% |
Shares Outstanding (Basic) | 76 | 76 | 78 | 81 | 77 | 61 |
Shares Outstanding (Diluted) | 76 | 76 | 78 | 81 | 77 | 61 |
Shares Change | 0.72% | -1.74% | -3.66% | 4.35% | 27.78% | -0.00% |
EPS (Basic) | 0.08 | 0.29 | 0.52 | 0.63 | 0.53 | 0.86 |
EPS (Diluted) | 0.08 | 0.29 | 0.52 | 0.63 | 0.53 | 0.86 |
EPS Growth | -85.67% | -44.66% | -17.23% | 18.84% | -38.73% | 4.58% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Free Cash Flow | -21.52 | -17.44 | -80.73 | -68.79 | 12.83 | 37.83 |
Free Cash Flow Per Share | -0.28 | -0.23 | -1.04 | -0.85 | 0.17 | 0.62 |
Dividend Per Share | 0.145 | 0.145 | 0.260 | 0.260 | 0.160 | 0.130 |
Dividend Growth | -44.23% | -44.23% | 0% | 62.50% | 23.08% | - |
Gross Margin | 73.45% | 75.71% | 76.15% | 79.81% | 81.44% | 83.55% |
Operating Margin | -1.19% | 6.69% | 14.65% | 11.87% | 14.20% | 16.89% |
Profit Margin | 2.83% | 9.32% | 15.71% | 22.40% | 15.94% | 18.21% |
Free Cash Flow Margin | -10.35% | -7.43% | -31.49% | -30.51% | 5.02% | 13.24% |
EBITDA | 38.62 | 50.78 | 59.98 | 45.32 | 54.77 | 66.96 |
EBITDA Margin | 18.57% | 21.62% | 23.39% | 20.10% | 21.44% | 23.44% |
D&A For EBITDA | 41.1 | 35.08 | 22.42 | 18.55 | 18.49 | 18.71 |
EBIT | -2.48 | 15.7 | 37.57 | 26.77 | 36.28 | 48.25 |
EBIT Margin | -1.19% | 6.69% | 14.65% | 11.87% | 14.20% | 16.89% |
Effective Tax Rate | - | 5.23% | 13.43% | 13.39% | 19.25% | 12.14% |
Revenue as Reported | 234.84 | 234.84 | 256.41 | 225.49 | 255.47 | 285.66 |